Aller au contenu

A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors

Nom du journal : Invest New Drugs

Année : 2021

Volume : 39

Page de départ : 1089

Page de fin : 1098

Auteurs: Azaro A, Benhadji KA, Cassier PA, Massard C, Italiano A, Tap WD, Merchan J, Anderson B, Yuen E, Yu D, Oakley G, Pant S,